Ischemic Heart Disease (IHD) Drugs Market Report 2026

The ischemic heart disease (ihd) drugs market size has grown steadily in recent years. It will grow from $6.65 billion in 2025 to $6.9 billion in 2026 at a compound annual growth rate (CAGR) of 3.7%. The growth in the historic period can be attributed to rising prevalence of coronary artery disease, increasing geriatric population, growing awareness of cardiovascular health, high incidence of lifestyle-related risk factors, availability of generic drugs.

The ischemic heart disease (ihd) drugs market size is expected to see steady growth in the next few years. It will grow to $7.99 billion in 2030 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to advancements in precision medicine, integration of digital health solutions, growth in combination therapy adoption, development of novel drug delivery systems, expansion of telehealth and remote monitoring. Major trends in the forecast period include personalized cardiac therapy, combination drug formulations, telemedicine-enabled cardiac care, cardiovascular risk prediction & monitoring, minimally invasive drug delivery.

The rising prevalence of heart failure is expected to drive the expansion of the ischemic heart disease (IHD) drug market in the coming years. Heart failure is a long-term condition in which the heart is unable to pump sufficient blood to meet the body’s demand for oxygen and nutrients, often resulting in symptoms such as fatigue, breathlessness, and reduced ability to carry out daily activities. Ischemic heart disease (IHD) medications play a critical role in managing heart failure by helping to reduce risk factors and alleviate symptoms associated with ischemic heart disease, thereby lowering the likelihood of heart failure progression. These drugs suppress the heart’s pacemaker activity and are particularly beneficial for heart failure patients with reduced ejection fraction and elevated resting heart rates who are already receiving tolerated beta-blocker therapy. For instance, in September 2023, the Heart Failure Society of America, a US-based organization, reported that approximately 6.7 million Americans aged 20 and older were living with heart failure, with prevalence projected to increase to 8.5 million by 2030. Therefore, the growing incidence of heart failure is contributing to the growth of the ischemic heart disease (IHD) drug market.

Major companies operating in the ischemic heart disease (IHD) drug market are concentrating on securing regulatory approvals and broadening drug indications to enhance treatment options and gain a larger share of the market. For instance, in June 2023, Bristol Myers Squibb, a US-based biopharmaceutical company, announced that the European Commission had approved Camzyos (mavacamten), the first allosteric and selective cardiac myosin inhibitor for the treatment of symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy (HCM). In the same year in the United States, the Food and Drug Administration approved a supplemental new drug application supported by Phase 3 VALOR HCM trial data, which demonstrated a significant reduction in patients’ eligibility for septal reduction therapy. Therefore, increasing regulatory activity and expanded indications for myosin inhibitors are driving growth in the IHD drug market.

In March 2024, Novo Nordisk, a Denmark-based pharmaceutical company, acquired Cardior Pharmaceuticals for an undisclosed amount. This acquisition represents a key step in Novo Nordisk’s strategy to build and expand its cardiovascular disease portfolio, an area associated with high global mortality rates. Cardior Pharmaceuticals is a Germany-based pharmaceutical company focused on the development and manufacture of cardiovascular therapies for ischemic heart disease.

Major companies operating in the ischemic heart disease (ihd) drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., Novitium Pharma LLC.

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ischemic heart disease (ihd) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the ischemic heart disease drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and excipients, leading to higher production expenses. This impact is particularly significant in segments such as anti-dyslipidemic drugs and antithrombotic agents, and in regions like North America and Europe where imports are substantial. While tariffs have caused supply chain disruptions and price adjustments, they have also incentivized local manufacturing investments and the development of cost-efficient production strategies, partially offsetting negative effects.

The ischemic heart disease (ihd) drugs market research report is one of a series of new reports that provides ischemic heart disease (ihd) drugs market statistics, including ischemic heart disease (ihd) drugs industry global market size, regional shares, competitors with a ischemic heart disease (ihd) drugs market share, detailed ischemic heart disease (ihd) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ischemic heart disease (ihd) drugs industry. This ischemic heart disease (ihd) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ischemic heart disease (IHD) drugs are medications prescribed to treat and control a condition in which blood flow to the heart muscle is reduced, most commonly due to narrowing of the coronary arteries. These drugs are intended to relieve symptoms, lower the risk of complications such as heart attacks, and enhance overall heart function.

The major drug classes used in ischemic heart disease (IHD) treatment include anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), vasodilators, and antithrombotic agents. Anti-dyslipidemic drugs are medications designed to reduce abnormal lipid levels, such as cholesterol and triglycerides, in the blood to decrease the risk of cardiovascular conditions. These drugs are used to manage various disease categories, including angina pectoris and myocardial infarction, and are utilized by different end users such as hospital pharmacies, retail pharmacies, and online pharmacies.

The ischemic heart disease (IHD) drugs market consists of sales of antiarrhythmic drugs, anticoagulants, anti-anginal medications, nitroglycerin and nitrates, statins, and antiplatelet agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.